Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | Q9HBH1 | 2/20 | 0.42 | |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | BMP1 | P13497 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601223 | 1.00 | PDF (0.42) | PDFTSHRKMT2AMEN1POLB | |
| SCHEMBL4602747 | 0.93 | PDF (0.41) | PDFTSHRBMP1LMNA | |
| SCHEMBL4604487 | 0.93 | KMT2A (0.41) | PDFTSHRKMT2AMEN1 | |
| SCHEMBL4602320 | 0.93 | NPSR1 (0.46) | PDFKMT2AMEN1BMP1 | |
| SCHEMBL4602355 | 0.91 | KMT2A (0.43) | PDFTSHRKMT2AMEN1BMP1 | |
| SCHEMBL4603007 | 0.89 | NPC1 (0.41) | TSHRKMT2AMEN1POLBLMNA | |
| SCHEMBL14066495 | 0.85 | MMP2 (0.45) | PDFKMT2AMEN1BMP1 | |
| SCHEMBL4887279 | 0.84 | MMP3 (0.51) | PDFBMP1 | |
| SCHEMBL4886049 | 0.83 | KMT2A (0.43) | TSHRKMT2AMEN1POLB | |
| SCHEMBL4886058 | 0.83 | KMT2A (0.43) | TSHRKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | KANG JAE-HOON | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | PDF, PEPD, DHPS | PDF 1/4885TSHR 3586/4885KMT2A 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.